April 11, 2022 11:15 AM EDTUpdated 02:15 PM
R&D

AACR22: Bris­tol My­er­s' Op­di­vo is yet to reach sur­vival end­point in ear­ly-stage lung can­cer. But will it mat­ter?

Max Gelman

Senior Editor

NEW OR­LEANS — Fresh off a land­mark ap­proval for its block­buster check­point in­hibitor Op­di­vo, Bris­tol My­ers Squibb is tout­ing new da­ta at AACR it hopes will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

A service from the Financial Times